Literature DB >> 29350338

Reversible Suppression of Lymphoproliferation and Thrombocytopenia with Rapamycin in a Patient with Common Variable Immunodeficiency.

Elissa K Deenick1,2, Adrienne Morey3, Mark Danta2, Louise Emmett4, Keith Fay5, Gary Gracie6, Cindy S Ma1,2, Rebecca Macintosh7, Sandy A B C Smith8, Sarah C Sasson8, William A Sewell8, Mark Cowley9, Stuart G Tangye1,2, Anthony D Kelleher10, Tri G Phan11,12.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29350338     DOI: 10.1007/s10875-018-0477-z

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


× No keyword cloud information.
  9 in total

Review 1.  How I treat common variable immune deficiency.

Authors:  Charlotte Cunningham-Rundles
Journal:  Blood       Date:  2010-03-23       Impact factor: 22.113

2.  Morbidity and mortality in common variable immune deficiency over 4 decades.

Authors:  Elena S Resnick; Erin L Moshier; James H Godbold; Charlotte Cunningham-Rundles
Journal:  Blood       Date:  2011-12-16       Impact factor: 22.113

3.  Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients.

Authors:  G K Wong; S Goldacker; C Winterhalter; B Grimbacher; H Chapel; M Lucas; D Alecsandru; D McEwen; I Quinti; H Martini; C Milito; R E Schmidt; D Ernst; T Espanol; A Vidaller; J Carbone; E Fernandez-Cruz; V Lougaris; A Plebani; N Kutukculer; L I Gonzalez-Granado; R Contreras; S Kiani-Alikhan; M A A Ibrahim; J Litzman; A Jones; H B Gaspar; L Hammarstrom; U Baumann; K Warnatz; A P Huissoon
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

4.  The EUROclass trial: defining subgroups in common variable immunodeficiency.

Authors:  Claudia Wehr; Teemu Kivioja; Christian Schmitt; Berne Ferry; Torsten Witte; Efrem Eren; Marcela Vlkova; Manuel Hernandez; Drahomira Detkova; Philip R Bos; Gonke Poerksen; Horst von Bernuth; Ulrich Baumann; Sigune Goldacker; Sylvia Gutenberger; Michael Schlesier; Florence Bergeron-van der Cruyssen; Magali Le Garff; Patrice Debré; Roland Jacobs; John Jones; Elizabeth Bateman; Jiri Litzman; P Martin van Hagen; Alessandro Plebani; Reinhold E Schmidt; Vojtech Thon; Isabella Quinti; Teresa Espanol; A David Webster; Helen Chapel; Mauno Vihinen; Eric Oksenhendler; Hans Hartmut Peter; Klaus Warnatz
Journal:  Blood       Date:  2007-09-26       Impact factor: 22.113

5.  Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome.

Authors:  David T Teachey; Robert Greiner; Alix Seif; Edward Attiyeh; Jack Bleesing; John Choi; Catherine Manno; Eric Rappaport; Dirk Schwabe; Cecilia Sheen; Kathleen E Sullivan; Hongming Zhuang; Daniel S Wechsler; Stephan A Grupp
Journal:  Br J Haematol       Date:  2009-02-04       Impact factor: 6.998

6.  Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.

Authors:  Hye Sun Kuehn; Weiming Ouyang; Bernice Lo; Elissa K Deenick; Julie E Niemela; Danielle T Avery; Jean-Nicolas Schickel; Dat Q Tran; Jennifer Stoddard; Yu Zhang; David M Frucht; Bogdan Dumitriu; Phillip Scheinberg; Les R Folio; Cathleen A Frein; Susan Price; Christopher Koh; Theo Heller; Christine M Seroogy; Anna Huttenlocher; V Koneti Rao; Helen C Su; David Kleiner; Luigi D Notarangelo; Yajesh Rampertaap; Kenneth N Olivier; Joshua McElwee; Jason Hughes; Stefania Pittaluga; Joao B Oliveira; Eric Meffre; Thomas A Fleisher; Steven M Holland; Michael J Lenardo; Stuart G Tangye; Gulbu Uzel
Journal:  Science       Date:  2014-09-11       Impact factor: 47.728

7.  Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency.

Authors:  Carrie L Lucas; Hye Sun Kuehn; Fang Zhao; Julie E Niemela; Elissa K Deenick; Umaimainthan Palendira; Danielle T Avery; Leen Moens; Jennifer L Cannons; Matthew Biancalana; Jennifer Stoddard; Weiming Ouyang; David M Frucht; V Koneti Rao; T Prescott Atkinson; Anahita Agharahimi; Ashleigh A Hussey; Les R Folio; Kenneth N Olivier; Thomas A Fleisher; Stefania Pittaluga; Steven M Holland; Jeffrey I Cohen; Joao B Oliveira; Stuart G Tangye; Pamela L Schwartzberg; Michael J Lenardo; Gulbu Uzel
Journal:  Nat Immunol       Date:  2013-10-28       Impact factor: 25.606

8.  Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.

Authors:  Desirée Schubert; Claudia Bode; Rupert Kenefeck; Tie Zheng Hou; Lucy S K Walker; David M Sansom; Bodo Grimbacher; James B Wing; Alan Kennedy; Alla Bulashevska; Britt-Sabina Petersen; Alejandro A Schäffer; Björn A Grüning; Susanne Unger; Natalie Frede; Ulrich Baumann; Torsten Witte; Reinhold E Schmidt; Gregor Dueckers; Tim Niehues; Suranjith Seneviratne; Maria Kanariou; Carsten Speckmann; Stephan Ehl; Anne Rensing-Ehl; Klaus Warnatz; Mirzokhid Rakhmanov; Robert Thimme; Peter Hasselblatt; Florian Emmerich; Toni Cathomen; Rolf Backofen; Paul Fisch; Maximilian Seidl; Annette May; Annette Schmitt-Graeff; Shinji Ikemizu; Ulrich Salzer; Andre Franke; Shimon Sakaguchi
Journal:  Nat Med       Date:  2014-10-20       Impact factor: 53.440

9.  Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage.

Authors:  Ivan Angulo; Oscar Vadas; Fabien Garçon; Edward Banham-Hall; Vincent Plagnol; Timothy R Leahy; Helen Baxendale; Tanya Coulter; James Curtis; Changxin Wu; Katherine Blake-Palmer; Olga Perisic; Deborah Smyth; Mailis Maes; Christine Fiddler; Jatinder Juss; Deirdre Cilliers; Gašper Markelj; Anita Chandra; George Farmer; Anna Kielkowska; Jonathan Clark; Sven Kracker; Marianne Debré; Capucine Picard; Isabelle Pellier; Nada Jabado; James A Morris; Gabriela Barcenas-Morales; Alain Fischer; Len Stephens; Phillip Hawkins; Jeffrey C Barrett; Mario Abinun; Menna Clatworthy; Anne Durandy; Rainer Doffinger; Edwin R Chilvers; Andrew J Cant; Dinakantha Kumararatne; Klaus Okkenhaug; Roger L Williams; Alison Condliffe; Sergey Nejentsev
Journal:  Science       Date:  2013-10-17       Impact factor: 47.728

  9 in total
  1 in total

1.  Germline-activating mutations in PIK3CD compromise B cell development and function.

Authors:  Danielle T Avery; Alisa Kane; Tina Nguyen; Anthony Lau; Akira Nguyen; Helen Lenthall; Kathryn Payne; Wei Shi; Henry Brigden; Elise French; Julia Bier; Jana R Hermes; David Zahra; William A Sewell; Danyal Butt; Michael Elliott; Kaan Boztug; Isabelle Meyts; Sharon Choo; Peter Hsu; Melanie Wong; Lucinda J Berglund; Paul Gray; Michael O'Sullivan; Theresa Cole; Steven M Holland; Cindy S Ma; Christoph Burkhart; Lynn M Corcoran; Tri Giang Phan; Robert Brink; Gulbu Uzel; Elissa K Deenick; Stuart G Tangye
Journal:  J Exp Med       Date:  2018-07-17       Impact factor: 14.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.